Lupin Limited has informed the Exchange about execution of Business Transfer Agreement for transfer of its API R&D Division situated at Pune, to Lupin Manufacturing Solutions Limited, a wholly owned subsidiary of the Company, on a slump sale basis.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has signed a Business Transfer Agreement (BTA) to transfer its API (Active Pharmaceutical Ingredient) R&D Division located in Pune to Lupin Manufacturing Solutions Limited, a wholly owned subsidiary of the company. The transfer will happen on a slump sale basis, meaning the division is being sold as a single going concern at an agreed lump-sum value rather than asset-by-asset. The transaction is effective from July 1, 2025, and Lupin has confirmed the deal has been completed. This follows earlier intimations dated March 31, 2025 and April 30, 2025 regarding the proposed transfer.
This is an internal restructuring within the Lupin group since the API R&D division is moving to a wholly owned subsidiary, so shareholders remain indirectly exposed to the business. It is unlikely to have a material impact on the stock price, but signals tighter operational focus and possibly sets the stage for the subsidiary to take on independent roles in future partnerships or value creation.